Bronchoalveolar galactomannan in invasive pulmonary aspergillosis: a prospective study in pediatric patients.

BACKGROUND: Elevations in the number of immunocompromised patients in the past decade has lead to progressive increase in the incidence of Invasive Pulmonary Aspergillosis (IPA) among children; however, early diagnosis remains a challenge. Detection of galactomannan (GM) in the bronchoalveolar lavage (BAL) fluid appears to possess higher sensitivity and specificity than serum in immunocompromised adult patients but, it rarely has been investigated in pediatric patients. METHODS: We performed a prospective case-control study to evaluate the efficacy of BAL GM in immunocompromised pediatric patients. Cases were subjects fulfilling the host factor criteria as defined by the EORTC/MSG and met established definitions for proven or probable IPA. Control group was patients with possible IPA in whom diagnoses other than IPA were confirmed and patients without risk factors of IPA who underwent bronchoscopy for other diagnostic purpose. Galactomannan testing was performed on BAL fluid samples using platelia Aspergillus seroassay. RESULTS: Sixteen cases of IPA (4 proven, 12 probable) and 54 controls (6 possible IPA and 48 no IPA) were documented according to EORTC/MSG definitions. The sensitivity and positive predictive values of BAL GM using an OD index of ≥0.5 were 87.5% and 93.33% respectively. We found seven cases of IPA with negative serum GM while their BAL GM was positive. CONCLUSION: We found high diagnostic value of BAL GM in immunocompromised pediatric patients with IPA. The lower OD index is necessary in children to avoid missing the cases of IPA in children.

Anti-cyclic citrullinated peptide (CCP) antibody in patients with wood-smoke-induced chronic obstructive pulmonary disease (COPD) without rheumatoid arthritis.

Citrullination, a post-translational modification of proteins, is increased in inflammatory processes and is known to occur in smokers. It can induce anti-cyclic citrullinated peptide (CCP) antibodies, the most specific serologic marker for rheumatoid arthritis. Thus far, the incidence of autoimmunity in patients with wood-smoke-induced chronic obstructive pulmonary disease (COPD) resulting in anti-CCP production has not been examined. We hypothesise that anti-CCP antibody level in these patients should be higher than that in healthy subjects. A total of 112 non-rheumatoid arthritis patients, including 56 patients with wood-smoke-induced COPD and 56 patients with tobacco-induced COPD, and 56 healthy non-smoker controls were included. The serum anti-CCP antibody levels were measured and compared between the groups and against smoke exposure and clinical characteristics. The mean anti-CCP antibody levels in wood-smoke-induced COPD group were significantly higher than those in tobacco-induced COPD group (p = 0.03) and controls (p = 0.004). Furthermore, 8 (14.2 %) patients with wood-smoke-induced COPD, 4 (7.14 %) with tobacco-induced COPD and 2 (3.57 %) controls exceeded the conventional cut-off of anti-CCP antibody positivity. No relationship was found between the anti-CCP antibody level and age, gender, duration of disease, Pack-years of smoking, and duration of exposure to wood smoke. Moreover, correlations between anti-CCP antibodies and severity of airflow limitation, CAT scores, mMRC scores of dyspnoea, and GOLD staging of COPD severity were not significant. Wood-smoke-induced COPD could significantly increase the anti-CCP antibody level in non-rheumatoid arthritis patients when compared with that in patients with tobacco-induced COPD and healthy controls.

Validation of Persian Version of Asthma Control Test Based on new Global Initiative for Asthma Guidelines.

BACKGROUND: Asthma is a serious global health problem. The lack of a clinical gold standard for evaluation of asthma control, as well as inadequate recognition of uncontrolled asthma by patients and clinicians may contribute to this situation. The Asthma Control Test is an easy and reliable test. The aim of this study was to validate the Persian version of this test with regard to GINA2009 guidelines based on a specialist's rating of asthma control. MATERIALS AND METHODS: Patients (n = 150) completed the Asthma Control Test. Pulmonary function was measured. A chest specialist rated asthma control in line with the Global Initiative for Asthma 2009 guidelines. Patients were divided into well controlled, partly controlled and uncontrolled groups in order to evaluate the reliability and validity of the ACT. RESULTS: The mean age was 41.68 years. The internal consistency reliability of 5-item ACT survey was 0.89%. There were no significant differences in ACT scores between different age, gender, educational status and inhabitancy groups. Between the groups with different GINA-based control levels, a significant difference in ACT score was noted in favor of an ACT-based discrimination of different states of asthma control (F = 305.3, P < 0.001). Patient group with poorer lung function (FEV1) scored significantly lower on the ACT than groups with better lung function (F = 6.82, P < 0.001). Differences in ACT score between treatment recommendation groups were significant (F = 50.54, P < 0.001). Statistically significant correlations were observed between ACT scores and GINA-based values of asthma control rating by a specialist (r = 0.86, p < 0.001) and treatment recommendations (r = 0.54, p < 0.001). Correlation between ACT score and percentage of FEV1 predicted was moderate (r = 0.39, P < 0.001). CONCLUSION: The Persian version of Asthma Control Test is a valid and reliable test for asthma control assessment.

Anthracosis and anthracofibrosis.

OBJECTIVE: To define the clinical, radiographic, and bronchoscopic features, and to describe the occupations of the largest group of patients with anthracosis. METHODS: All patients who underwent flexible bronchoscopy at 2 Iranian hospitals (Imam Hospital [Tehran], and Tohid Hospital [Sanandaj]), Iran, between April 1982 and June 2006 were considered for inclusion in the study. The demographic data, clinical, and radiographic findings of anthracotic and anthracofibrotic patients were recorded. RESULTS: Of the 14,300 patients, 487 cases of simple anthracosis, and 291 of anthracofibrosis were found. A total of 98.4% female patients were housewives, and 86.4% lived in rural areas. Of the male patients, 40.6% were farmers, 29.6% were manual workers, and 7.5% were miners. Of these, 96% of patients had abnormal chest radiography. On bronchoscopic examination, bilateral bronchial involvement was found in 62.5% of the patients. The condition was confined to the trachea in 0.38% of patients, the bronchi involved were the main bronchus in 37%, the lobar bronchi in 83.2%, and segmental bronchi in 35%. Bronchial narrowing and obstruction was observed in 37.4% of the patients. CONCLUSION: Anthracosis and anthracofibrosis are neglected conditions that are a common finding on routine bronchoscopic examination. Given the demographic findings, and a review of other reports from developing countries, exposure to combustion of biomass fuel in rural areas is a possible risk factor.